Drug Discovery World

MAY 11, 2023

Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases. Another dangerous consequence can occur when the therapeutic or vaccine introduces proteins that can activate an uncontrolled immune response. 2015): 1727-1737. Collins, Ben C.,

Production 130

Production Vaccine Immune Response Therapies 130

The Pharma Data

JULY 21, 2021

We believe that our mRNA technology can be used to develop vaccine candidates addressing other diseases as well. Pfizer and Biovac have worked together since 2015 on the sterile formulation, fill, finish and distribution of the Prevenar 13 vaccine. CEO and Co-founder of BioNTech. “We AUTHORIZED USE IN THE U.S.:

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Discovery World

JULY 31, 2023

While concern swirled around its rapid development, mRNA- based programmes for infectious disease and cancer had been in place in biopharmaceutical companies for over a decade. The expansion of nucleic acid-based therapies One factor contributing to increased investment during this time was the success of the mRNA-based Covid-19 vaccine.

DNA 130

DNA Vaccine Therapies Production 130

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immune response while minimising toxicity.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

AUGUST 17, 2021

In the Opdivo plus Yervoy arm, patients received treatment with Opdivo 3 mg/kg every 2 weeks and Yervoy 1 mg/kg every 6 weeks up to 24 months or until disease progression or unacceptable toxicity. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. Half of people diagnosed with cancer in England and Wales survive their disease for 10 years or more (2010-11) 1. This continues to be the standard of care.

Research 130

Research Therapies Immune Response Clinical Trials 130

The Pharma Data

APRIL 3, 2021

The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. Department of Health and Human Services (HHS).

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 18, 2021

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Following today’s FDA approval, the U.S. Jansen, Ph.D.,

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

APRIL 9, 2021

The results for these Opdivo -based combinations represent a significant advancement for patients with esophageal cancer who are often diagnosed after their disease has spread and would benefit from new therapeutic options,” said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb. About Esophageal Cancer.

Clinical Trials 52

Clinical Trials Trials Immune Response Treatment 52

The Pharma Data

MARCH 29, 2022

“Lung cancer is the leading cause of cancer deaths globally, and unfortunately cases caught in earlier stages continue to contribute to this statistic, with up to 55% of patients who undergo surgery ultimately relapsing and dying of their disease,” said Abderrahim Oukessou, M.D., About Opdivo.

Treatment 52

Treatment Clinical Trials Trials Immune Response 52

The Pharma Data

SEPTEMBER 8, 2021

Updated Phase 3 CheckMate -577 disease-free survival (DFS) results for adjuvant Opdivo treatment vs. placebo for patients with resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy (CRT). About Opdivo. On March 25, 2011, the U.S.

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

JULY 8, 2021

“Severe asthma is a challenging, complex disease for physicians and millions of patients and has a high unmet medical need,” said David M. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.(24,25) Reese, M.D.,

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

APRIL 16, 2021

Two Opdivo -based therapies are now authorized for first-line treatment of patients with advanced renal cell carcinoma in the European Union: Opdivo plus Yervoy , a standard of care in intermediate- or poor-risk disease, and Opdivo in combination with Cabometyx , approved regardless of risk status. PRINCETON, N.J.–(BUSINESS

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

The Pharma Data

APRIL 11, 2021

Additionally, Opdivo plus chemotherapy was well tolerated and showed consistent improvements in pCR regardless of PD-L1 expression levels, histologies or stages of disease. The ultimate goal of treatment in earlier stages of cancer is to prevent the disease from coming back as we work towards a cure for these patients. About Opdivo.

Trials 52

Trials Treatment Immune Response Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

29, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the potential pathway to marketing approval for its lead product candidate remestemcel-L. NEW YORK, Oct.

Treatment 40

Treatment Trials Production Disease 40

The Pharma Data

MARCH 31, 2023

months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression or death by 32%, demonstrating a landmark three-year event-free survival (EFS) rate of 57% with Opdivo with chemotherapy compared to 43% with chemotherapy alone (Hazard Ratio [HR], 0.68; 95% Confidence Interval [CI], 0.49 With median follow up of 41.4

Trials 40

Trials Clinical Trials Treatment Immune Response 40

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 6,7 Approximately 10% of asthma patients have severe asthma.

Trials 52

Trials Production Clinical Trials Government 52

Drug Discovery World

SEPTEMBER 29, 2022

Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need. . Allison August, M.D., The potential future of mRNA in CMV prevention .

Vaccine 130

Vaccine Immune Response Virus Disease 130

The Pharma Data

JUNE 30, 2021

The EC’s decision is based on results from the Phase 2 CheckMate -142 trial in which Opdivo plus Yervoy demonstrated a clinically meaningful improvement in objective response rate (ORR) in patients with MSI-H/dMMR mCRC who received prior treatment with fluoropyridine, oxaliplatin and irinotecan. Waxman, M.D., About Opdivo.

Treatment 52

Treatment Trials FDA Approval Disease 52

The Pharma Data

MARCH 11, 2021

Opdivo and Opdivo -based combinations are important treatment options in multiple forms of cancer, with established long-term survival benefits in complex diseases, including metastatic melanoma, renal cell carcinoma and non-small cell lung cancer. About Opdivo.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

AUGUST 11, 2020

Responses to the current standard chemotherapy in patients are short lived, and less than 6% of patients with metastatic disease survive beyond five years,” said Yelena Y. All patients continued treatment for two years or until disease progression, unacceptable toxicity or withdrawal of consent. Janjigian, M.D., About Opdivo.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

MAY 13, 2021

Health authorities in Guinea officially declared a new Ebola outbreak in February 2021 after the West African country experienced its first cases of disease since the end of the 2014-2016 Ebola outbreak – which was the worst on record. Pregnant women and HIV-positive adults who are otherwise healthy are permitted to enroll in the program.

Vaccine 52

Vaccine Virus Pharmaceutical Companies Clinical Trials 52

The Pharma Data

JULY 8, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Pharmaceutical Companies Disease 52

The Pharma Data

JULY 6, 2021

In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, M.D., 2) variants during the study period.

Vaccine 52

Vaccine Immune Response Clinical Trials Hospitals 52

The Pharma Data

JANUARY 29, 2021

Prevention of severe disease; protection against COVID-related hospitalization and death The vaccine candidate was 85 percent effective in preventing severe disease across all regions studied, [i] 28 days after vaccination in all adults 18 years and older. Global Head, Janssen Research & Development.

Vaccine 40

Vaccine Trials Pharmaceutical Companies Immune Response 40

PLOS: DNA Science

JULY 25, 2024

On Call , Dr. Anthony Fauci’s memoir, is a riveting read that ricochets through infectious disease challenges since the early 1980s. A virus that directly attacks the immune response presents a special challenge. It made headlines in 2015 with hundreds of thousands of cases in Brazil.

Virus 87

Virus Science Vaccine Government 87